Web Exclusives

Pearls for Boosting Clinical Trial Participation in Underrepresented Populations
Web Exclusives — August 21, 2024
Encouraging diverse populations to participate in clinical trials is key as new FDA guidance released.
Read Article

Web Exclusives — July 1, 2024
Colorectal cancer (CRC) is the second most common cause of cancer-related death in the United States and is the leading cause of death in men aged <50 years.
Read Article

Web Exclusives — June 28, 2024
On June 26, 2024, the FDA approved epcoritamab-bysp (Epkinly; Abbvie and Genmab) as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after ≥2 lines of prior therapy.
Read Article

Web Exclusives — June 18, 2024
FDA officials approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma efficacy of this treatment was evaluated in KEYNOTE-868/NRG-GY018.
Read Article

Web Exclusives — May 14, 2024
Despite ranking among the top 6 wealthiest economies in the world per capita, the United States still has sizable health disparities among its citizens, which are rooted in social, economic, and environmental factors. Place of birth is more strongly associated with life expectancy than race or genetics.
Read Article

Web Exclusives — April 15, 2024
Recognizing the complexities of treatment with oral medications is an important step toward successful outcomes.
Read Article

Web Exclusives — August 7, 2023
On July 19, 2023, an EF3 tornado touched down in Rocky Mount, NC, badly damaging a Pfizer drug manufacturing facility that is responsible for producing nearly 25% of Pfizer’s sterile injectable medicines used in US hospitals.
Read Article

Web Exclusives — January 31, 2023
One-year follow-up data from a phase 3 study found similar duration of response, time to progression (TTP), and survival rates with the biosimilar candidate CT-P16 compared with its reference drug, bevacizumab (Avastin), in the first-line treatment of patients with metastatic or recurrent nonsquamous non–small-cell lung cancer (NSCLC).
Read Article

Web Exclusives — December 5, 2022
In an interview, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
Read Article

Web Exclusives — October 19, 2021
Gallium-68 PSMA PET/CT imaging in patients with early relapsed prostate cancer confirms the reliability of this imaging modality in local and metastatic lesion detection.
Read Article

Page 4 of 14